Corbus Pharmaceuticals Holdings (CRBP) Cash from Operations (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Cash from Operations for 13 years, with the latest figure at -$15.6 million in Q3 2025.

• On a quarterly basis, Cash from Operations fell 11.53% year-over-year to -$15.6 million in Q3 2025; TTM through Sep 2025 was -$59.5 million, a 61.45% decrease from a year earlier, with the FY2024 full-year figure at -$41.8 million, down 15.77% from the prior year.
• Cash from Operations was -$15.6 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from -$16.6 million in the prior quarter.
• The five-year high for Cash from Operations was $856954.0 in Q3 2021, with the low at -$21.8 million in Q1 2021.
• Average Cash from Operations over 5 years is -$11.2 million, with a median of -$10.6 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash from Operations jumped 103.14% in 2021, then sank 945.44% in 2022.
• Over 5 years, Cash from Operations stood at -$9.7 million in 2021, then climbed by 23.16% to -$7.5 million in 2022, then rose by 19.41% to -$6.0 million in 2023, then sank by 82.12% to -$10.9 million in 2024, then sank by 42.11% to -$15.6 million in 2025.
• The last three Cash from Operations figures came in at -$15.6 million (Q3 2025), -$16.6 million (Q2 2025), and -$16.4 million (Q1 2025), per Business Quant data.